Skip to main content
Premium Trial:

Request an Annual Quote

Roche: Matthew Sause

Roche Diagnostics has named Matthew Sause as president and CEO, North America, effective Nov. 4. He replaces Jack Phillips, who left Roche at the end of August. Sause was previously the senior VP and head of global commercial product strategy at Gilead Sciences. From 2002 to 2014, Sause worked in the diagnostics division at Roche, filling US-based sales roles in molecular diagnostics, commercial operations positions in Asia, and country leadership in Ireland. In 2014, Sause moved to the pharmaceuticals division, where he was president of country operations in Peru and South Korea, before becoming VP and lifecycle leader for Roche's cancer drug Tecentriq.  

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.